Americans aged 60 and older are now able to receive a new RSV vaccine, but it is recommended that they first consult with their doctor, according to U.S. health officials. The Centers for Disease Control and Prevention (CDC) stated that the newly approved vaccines are expected to be available in the fall, along with flu shots and updated COVID-19 shots. Individuals who are eligible for the RSV vaccine should discuss with their doctor to determine if it is suitable for them.
The CDC also emphasized that adults with chronic heart or lung disease, weakened immune systems, and those living in long-term care facilities are at a higher risk for contracting the respiratory infection caused by RSV (respiratory syncytial virus). While RSV is a common cause of cold-like symptoms, it can be dangerous for infants and the elderly. Last year, there was a surge in RSV cases, resulting in overcrowded hospitals filled with wheezing children. Currently, there is no vaccine available for young children, but a vaccine for pregnant women to prevent illness in infants may be forthcoming pending approval from the Food and Drug Administration.
Last month, the FDA approved the RSV vaccines made by Pfizer and GSK for adults aged 60 and older. Acting CDC director Dr. Rochelle Walensky signed off on a recommendation from an advisory panel of outside experts supporting a single dose of these vaccines. The panel initially considered a stronger recommendation for all adults aged 65 and older to receive the vaccine but revised their endorsement due to concerns about its effectiveness in the frailest patients, the potential need for boosters, and the cost.
Drugmaker GSK informed the panel that their RSV vaccine would cost between $200 and $295, while Pfizer has not disclosed a price yet. The longevity of the vaccines over multiple seasons is still uncertain, and it remains to be seen whether boosters will be recommended. Some individuals advocated for a stronger endorsement for adults aged 65 and older, as it would increase the number of people receiving the vaccination. Robert Blancato, executive director of the National Association of Nutrition and Aging Services Programs, expressed this sentiment in a statement following the panel’s vote.
The Canadian Press © 2023
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
